Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC boosted its holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 236.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 35,989 shares of the company’s stock after acquiring an additional 25,278 shares during the quarter. Intech Investment Management LLC’s holdings in Atea Pharmaceuticals were worth $121,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd acquired a new position in Atea Pharmaceuticals during the third quarter worth about $37,000. Zacks Investment Management purchased a new stake in shares of Atea Pharmaceuticals during the 3rd quarter worth approximately $80,000. Virtu Financial LLC acquired a new stake in shares of Atea Pharmaceuticals in the 3rd quarter worth approximately $99,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Atea Pharmaceuticals in the 3rd quarter valued at approximately $148,000. Finally, HighTower Advisors LLC acquired a new position in Atea Pharmaceuticals during the fourth quarter worth $168,000. Institutional investors and hedge funds own 86.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, William Blair reissued an “outperform” rating on shares of Atea Pharmaceuticals in a report on Friday, March 7th.

Atea Pharmaceuticals Trading Down 5.0 %

NASDAQ:AVIR opened at $3.02 on Friday. The company has a market capitalization of $258.29 million, a P/E ratio of -1.46 and a beta of 0.18. The firm has a 50-day moving average price of $3.09 and a two-hundred day moving average price of $3.28. Atea Pharmaceuticals, Inc. has a twelve month low of $2.75 and a twelve month high of $4.15.

Atea Pharmaceuticals (NASDAQ:AVIR) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). On average, equities research analysts predict that Atea Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.